Cancer Vaccines Market: By Vaccine Type Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines) By Indication By Application and Region Forecast 2019-2030

Cancer Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine Type (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines) By Indication (Prostate Cancer, Cervical Cancer, Others) By Application (Preventive Vaccine, Therapeutic Vaccine) and Region Forecast 2019-2030

Cancer Vaccines Market size was valued at US$ 4.5 billion in 2023 and is poised to grow at a CAGR of 14.1% from 2024 to 2030. The global market provides a detailed overview of the market, which has been segmented by vaccine type, indication, and application. The market has been segmented by vaccine type into Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines. The Recombinant Cancer Vaccines segment is likely the largest and fastest-growing in terms of vaccine types. The market has been segmented into Prostate Cancer, Cervical Cancer, and Others. The Cervical Cancer segment gains the maximum revenue share in 2022-2028. The cancer vaccines are segmented on application into Preventive Vaccine and Therapeutic Vaccine.  

Cancer Vaccines Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

14.1%

Largest Market

Asia Pacific

Fastest Growing Market

North America

Cancer Vaccines Market Dynamics

The increasing number of cancer cases, rising investments, government support in cancer vaccine development, and technological advancements in cancer vaccine development are the factors driving the market's expansion.

Cancer Vaccines Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 4.5 billion

Market CAGR

14.1%

By Vaccine Type

  • Dendritic Cells (DC) Cancer Vaccines,
  • Recombinant Cancer Vaccines,
  • Antigen/Adjuvant Cancer Vaccines,
  • Viral Vector & DNA Cancer Vaccines

By Indication Type

  • Prostate Cancer,
  • Cervical Cancer,
  • Others

By Application

  • Preventive Vaccine,
  • Therapeutic Vaccine

By Region

  • North America (USA, Canada)
  • Europe (Germany, UK, France, Spain, Italy , Rest of Europe)
  • The Asia Pacific (China, India, Japan, Australia, South Korea, Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
  • MEA (Saudi Arabia, UAE, South Africa, Rest of MEA)

Key Features of the Report

  • The cancer vaccines market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis  

Download Free Sample Report

Frequently Asked Questions

The global cancer vaccines market size was valued at US$ 4.5 billion in 2023 and is poised to grow at a CAGR of 14.1% from 2024 to 2030.

The market players are CSL Limited, ADURO BIOTECH INC., Astellas Pharma Inc., Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Dendreon, ASTRAZENECA PLC., and OSE Immunotherapeutics.

North America is the fastest-growing region for the market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Cancer Vaccines Market Introduction
2.1. Global Cancer Vaccines Market - Taxonomy
2.2. Global Cancer Vaccines Market -Definitions
2.2.1. Vaccine Type
2.2.2. Indication
2.2.3. Application
2.2.4. Region
3. Global Cancer Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Current Trends
3.5. Global Cancer Vaccines Market Dynamic Factors - Impact Analysis
3.6. Mergers, Acquisitions, and Collaborations
4. Global Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cancer Vaccines Market, By Vaccine Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1. Dendritic Cells (DC) Cancer Vaccines
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Recombinant Cancer Vaccines
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Antigen/Adjuvant Cancer Vaccines
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Viral Vector & DNA Cancer Vaccines
5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Cancer Vaccines Market, By Indication, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.1. Prostate Cancer
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cervical Cancer
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Cancer Vaccines Market, By Application, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.1. Preventive Vaccine
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Therapeutic Vaccine
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Cancer Vaccines Market Forecast, By Region, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. MEA
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, and Country, 2024-2030
9. North America Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
9.1. Vaccine Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Dendritic Cells (DC) Cancer Vaccines
9.1.2. Recombinant Cancer Vaccines
9.1.3. Antigen/Adjuvant Cancer Vaccines
9.1.4. Viral Vector & DNA Cancer Vaccines
9.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Prostate Cancer
9.2.2. Cervical Cancer
9.2.3. Others
9.3. Application Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Preventive Vaccine
9.3.2. Therapeutic Vaccine
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.4.1. United States
9.4.2. Canada
9.5. North America Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027
9.6. North America Cancer Vaccines Market Dynamics - Trends
10. Europe Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
10.1. Vaccine Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Dendritic Cells (DC) Cancer Vaccines
10.1.2. Recombinant Cancer Vaccines
10.1.3. Antigen/Adjuvant Cancer Vaccines
10.1.4. Viral Vector & DNA Cancer Vaccines
10.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Prostate Cancer
10.2.2. Cervical Cancer
10.2.3. Others
10.3. Application Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Preventive Vaccine
10.3.2. Therapeutic Vaccine
10.4. Country Level Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.4.1. UK
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027
10.6. Europe Cancer Vaccines Market Dynamics - Trends
11. Asia Pacific Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
11.1. Vaccine Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Dendritic Cells (DC) Cancer Vaccines
11.1.2. Recombinant Cancer Vaccines
11.1.3. Antigen/Adjuvant Cancer Vaccines
11.1.4. Viral Vector & DNA Cancer Vaccines
11.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Prostate Cancer
11.2.2. Cervical Cancer
11.2.3. Others
11.3. Application Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Preventive Vaccine
11.3.2. Therapeutic Vaccine
11.4. Country Level Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. ANZ
11.4.4. Japan
11.4.5. Rest of APAC
11.5. Asia Pacific Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027
11.6. Asia Pacific Cancer Vaccines Market Dynamics - Trends
12. MEA Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
12.1. Vaccine Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Dendritic Cells (DC) Cancer Vaccines
12.1.2. Recombinant Cancer Vaccines
12.1.3. Antigen/Adjuvant Cancer Vaccines
12.1.4. Viral Vector & DNA Cancer Vaccines
12.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Prostate Cancer
12.2.2. Cervical Cancer
12.2.3. Others
12.3. Application Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Preventive Vaccine
12.3.2. Therapeutic Vaccine
12.4. Country Level Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
12.5. MEA Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027
12.6. MEA Cancer Vaccines Market Dynamics - Trends
13. Latin America Cancer Vaccines Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
13.1. Vaccine Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Dendritic Cells (DC) Cancer Vaccines
13.1.2. Recombinant Cancer Vaccines
13.1.3. Antigen/Adjuvant Cancer Vaccines
13.1.4. Viral Vector & DNA Cancer Vaccines
13.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Prostate Cancer
13.2.2. Cervical Cancer
13.2.3. Others
13.3. Application Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Preventive Vaccine
13.3.2. Therapeutic Vaccine
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Argentina
13.4.4. Rest of LA
13.5. Latin America Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027
13.6. Latin America Cancer Vaccines Market Dynamics - Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Anixa Biosciences Inc.
14.2.2. Dynavax Technologies Corporation
14.2.3. Vaccinogen, Inc.
14.2.4. Astrazeneca plc
14.2.5. Moderna Inc.
14.2.6. Vaccitech Limited
14.2.7. F Hoffmann-La Roche AG
14.2.8. GlaxoSmithKline PLC
14.2.9. Sanofi SA
14.2.10. Dendreon Pharmaceuticals LLC
15. Research Methodology
16. Key Assumptions and Acronyms

 

Key Market Players

  • Anixa Biosciences Inc.
  • Dynavax Technologies Corporation
  • Vaccinogen, Inc.
  • Astrazeneca plc
  • Moderna Inc.
  • Vaccitech Limited
  • F Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Dendreon Pharmaceuticals LLC

Related Industry Reports